KEGG   NETWORK: N10005Help
Entry
N10005                      Network                                

Name
First/second-generation tyrosine kinase inhibitor to EGFR mutation
Definition
(Gefitinib,Erlotinib,Afatinib,Dacomitinib) -| EGFR*
  Expanded
(D01977,D04023,D09733,D10514) -| 1956v2
Class
nt06210 ERK signaling
nt06266 Non-small cell lung cancer
nt06214 PI3K signaling
Type
Drug target
Gene
1956  EGFR; epidermal growth factor receptor
Variant
1956v2  EGFR mutation in non-small cell lung cancer
Perturbant
D01977  Gefitinib (first generation)
D04023  Erlotinib (first generation)
D09733  Afatinib (second generation)
D10514  Dacomitinib (second generation)
Reference
  Authors
Liao BC, Lin CC, Yang JC
  Title
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
  Journal
Curr Opin Oncol 27:94-101 (2015)
DOI:10.1097/CCO.0000000000000164
Reference
  Authors
Sharma SV, Bell DW, Settleman J, Haber DA
  Title
Epidermal growth factor receptor mutations in lung cancer.
  Journal
Nat Rev Cancer 7:169-81 (2007)
DOI:10.1038/nrc2088
LinkDB All DBs

DBGET integrated database retrieval system